{"name":"Highlightll Pharmaceutical (USA) LLC","slug":"highlightll-pharmaceutical-usa-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOU3hfa0JPVU9zTXZWc1A0WkRUYVhLZlB3c1RPc1FxVU1mSFBlN0lQT0tOMHlvbXJwRlZMbFhxdV9zTkxfWXBkUFdGcWZaQkFRMHpNMWFvUGpTVjlHZzluYXp4QXI5TlJrT0NXR2JwMGFrd3hZeFdyUzVuR0NuZnVuSkEzdjRRUEFqWXhPUjhsRXBEeUFIZl9jLVc1VVoyaHRmWFRVTWw0S3pFOV9xMlYzU2RpR2ZEV1dieWpjRTd4eElFY2V6UkdhdWNOd0NUUXk1Um95SjhVNHRRRUxXNGtzc2d4a2NkcjN3YmlUWEZCWTlkc2U4YlNyMW50XzFzdw?oc=5","date":"2026-02-16","type":"trial","source":"Investing News Network","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Investing News Network","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxOdERkUXowYm91d0VKWWo0SlBSWktzaGZwM3RJdm9kV0t1ZnhpZUFiVENMRmdJOWtUNXV6WmJZMEpBN3Q1X2d2TXFXOEEzNTZhRjd0N2E4Z1paRnVPenBtNllvT2JmbjBndUdTNGNpam83OGRrZDlGdVVNMWp0dHZ4SHRKb3hXMzBzN3Qxd01XQ1pmYVpDbkFpSWRaVGc4YUI0alViSW1xYjUzNXJDd3FwUlJRRktEdDVmU1BwYzJQNUpCYlVpbDdjeDVyMEMwYUlBUVZsZW1jSkRYMVhxMUU0UVN4R1luNDlfRVoxLWRDWm9NV3R5WTByRlRLTTNKeldweUhUSzNfZUs?oc=5","date":"2024-11-04","type":"trial","source":"GlobeNewswire","summary":"Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire","headline":"Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPbTNmZmQyaHYzOV9qaUpfUVZLWEk2QzhGLUlyZVJHU0xCNml4SldURjVzdktOSXE1S3JZYk0wT3ZKRkM2OVFBMk9IbWhQVzlwaE1VTEVjU0RWSGtueG5jVFhlby1OZlNKVzhCWmxYM1NfT2x5cC1JTDZnT1pwOWh6bURYRlZDbnRTdEp6TXVpRnVQZk43amc2UUx5MGwyQTFHVFhYUk45cjN1TWYzUktWQzNvRmppbVktd1M4a1ljaFdLS181RXlGclpGTGdHalZXREgyZElmcWo4TDFqdVhTM25SdkZQRnFFSmktamRWbDhNczNzSHEtRklTdGZpazk5S2lNY0NPSQ?oc=5","date":"2023-03-22","type":"deal","source":"prnewswire.com","summary":"Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders - prnewswire.com","headline":"Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disord","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}